 |
BIND is developing targeted nanoparticle therapeutics by applying their high throughput combinatorial platform that enables fabrication, screening and optimization of polymeric nanoparticles for a variety of therapeutic indications. These targeted nanoparticle therapeutics will enable the intracellular delivery of large payloads including small molecules, peptides, proteins and nucleic acids.
|
|
 |
 |
|
Scott Minick, President/CEO
|
|
 |
 |
|
